Company
Vertex Pharmaceuticals
Vertex Pharmaceuticals has 44 drugs tracked on RxWires: 2 post-market, 11 in Phase 3, 2 in Phase 2/3, 13 in Phase 2, 4 in Phase 1/2, 12 in Phase 1.
- Ticker
- VRTX
Pipeline
| Drug | Phase | Indication |
|---|---|---|
| Suzetrigine | Post-Market | Pain |
| Telaprevir | Post-Market | Hepatitis C |
| VX-659/TEZ/IVA | Phase 3 | Cystic Fibrosis |
| VX-445/TEZ/IVA | Phase 3 | Cystic Fibrosis |
| Biological/Vaccine | Phase 3 | Type 1 Diabetes |
| ELX/TEZ/IVA | Phase 3 | Cystic Fibrosis |
| ivacaftor | Phase 3 | Cystic Fibrosis |
| CTX001 | Phase 3 | Beta-Thalassemia |
| Povetacicept | Phase 3 | Immunoglobulin A Nephropathy |
| Pegylated Interferon Alfa 2a | Phase 3 | Hepatitis C |
| VX-121/TEZ/D-IVA | Phase 3 | Cystic Fibrosis |
| MP-424 | Phase 3 | Hepatitis C |
| LUM/IVA | Phase 3 | Cystic Fibrosis |
| VX-147 | Phase 2/3 | Proteinuric Kidney Disease |
| Exa-cel | Phase 2/3 | Sickle Cell Disease |
| VX-135 | Phase 2 | Chronic Hepatitis C |
| VX-765 | Phase 2 | Psoriasis |
| VX-121 | Phase 2 | Cystic Fibrosis |
| VX-548 | Phase 2 | Painful Lumbosacral Radiculopathy |
| VX-670 | Phase 2 | Myotonic Dystrophy Type 1 (DM1) |
| VX-993 | Phase 2 | Diabetic Peripheral Neuropathic Pain |
| VX-150 | Phase 2 | Acute Pain |
| VX-814 | Phase 2 | Alpha 1-Antitrypsin Deficiency |
| Telaprevir and Sofosbuvir | Phase 2 | Hepatitis C, Chronic |
| VX-864 | Phase 2 | Alpha1-Antitrypsin Deficiency |
| VX-787 | Phase 2 | Influenza Virus |
| VX-561 | Phase 2 | Cystic Fibrosis |
| biricodar dicitrate | Phase 2 | Lung Cancer |
| VX-264 | Phase 1/2 | Type 1 Diabetes |
| IVA | Phase 1/2 | Cystic Fibrosis |
| VX-522 mRNA therapy | Phase 1/2 | Cystic Fibrosis |
| VCH-759 (BCH-27759) | Phase 1/2 | Hepatitis C, Chronic |
| lumacaftor | Phase 1 | Cystic Fibrosis |
| VX-973 | Phase 1 | Pain |
| Telaprevir; Moxifloxacin; Placebo | Phase 1 | Hepatitis C |
| 14C-VX-407 | Phase 1 | Autosomal Dominant Polycystic Kidney Disease (ADPKD) |
| VX-581 | Phase 1 | Cystic Fibrosis |
| Vanzacaftor | Phase 1 | Cystic Fibrosis |
| VX-809 | Phase 1 | Cystic Fibrosis |
| VX-770 | Phase 1 | In Development for Cystic Fibrosis |
| AVN-944 capsules for oral administration | Phase 1 | Acute Leukemia |
| VX-828 | Phase 1 | Cystic Fibrosis |
| VNZ/TEZ/D-IVA | Phase 1 | Cystic Fibrosis |
| IXP | Phase 1 | Focal Segmental Glomerulosclerosis (FSGS) |
Latest
- Povetacicept moved to Phase 3
- vertex pharmaceuticals filed 8-K
- vertex pharmaceuticals filed 8-K
- vertex pharmaceuticals filed 8-K
- vertex pharmaceuticals filed 8-K
Follow Vertex Pharmaceuticals on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.